TransCode Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 1, 2026. The filing reports a financing-related agreement and a potential debt-amortization trigger. It does not include operating results or a quarterly reporting period.
Business context and key financial terms
- Under an April 6, 2026 Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville), TransCode may sell up to $14 million of common stock. Yorkville also agreed to advance up to $6.0 million, less certain amounts, in two tranches in exchange for convertible promissory notes.
- After the October 1 prepayment, approximately $4.1 million of principal remained outstanding under the notes.
- The filing provides no revenue, profit, cash flow, margin, or liquidity figures. It does not give a clear value for the company’s cash balance or total debt.
Material event and change
- The notes define a Floor Price Event as daily VWAP below $1.72 for five trading days during any seven-consecutive-trading-day period. From September 11 through September 30, the stock’s daily VWAP was below $1.72 on 10 of 14 trading days.
- On October 1, the company prepaid $840,975: $759,000 of principal, a $75,900 prepayment premium, and $6,075 of accrued interest.
- In exchange, Yorkville waived any amortization event that may have occurred on or before September 30 and any such event through October 31, 2026.
Potential debt payments, outlook, and risks
- If an amortization event occurs, the notes require monthly payments beginning on the seventh trading day after the event. Payments generally include 18% of the outstanding principal as of the event date (or the remaining principal if lower), a 10% premium on the principal being paid, and accrued unpaid interest.
- Payments continue until the notes are repaid or the obligation ceases after daily VWAP exceeds the $1.72 Floor Price for 10 consecutive trading days, unless another amortization event occurs.
- The waiver provides temporary relief through October 31; the filing gives no broader financial guidance or operating outlook. Continued stock-price weakness could expose the company to payment obligations under the notes.
Important facts for investors to verify
- The remaining note principal and any subsequent repayments or conversions.
- Whether the stock satisfies the 10-consecutive-trading-day condition or another amortization event occurs after the waiver period.
- The company’s cash resources and ability to meet potential note payments; the filing does not provide a clear cash or liquidity value.
- Any future share sales under the up-to-$14 million equity purchase agreement and their potential dilution.